Adenocarcinoma of the esophagogastric junction (AEG) is an aggressive malignancy associated with poor prognosis, exhibiting increasing global incidence particularly in Western countries and East Asia [1–3]. While neoadjuvant chemotherapy (NAC) combined with surgical resection has become the standard therapeutic approach for locally advanced AEG, postoperative recurrence rates remain substantial, with 5-year survival rates below 40 % [4–6]. A study retrospectively analyzed 334 patients with esoph…